Effects of B cell depletion by rituximab, a monoclonal antibody to CD20, were studied in patients with relapsing MS that had not responded optimally to standard immunomodulatory therapies. Flow cytometry demonstrated reduced cerebrospinal fluid (CSF) B cells and T cells in most patients at 6 months post-treatment. ELISAs demonstrated modest reductions in serum antibodies to myelin oligodendrocyte glycoprotein and myelin basic protein in some subjects. Beta-interferon neutralizing antibodies were reduced in three subjects, but developed anew after treatment in three others, suggesting caution in considering rituximab as a means to eliminate NABs. In summary, rituximab depleted B cells from CSF at 24 weeks after initial treatment, and this B cell depletion was associated with a reduction in CSF T cells as well.
Introduction
Evidence implicates B cells and antibodies (Abs) in the pathogenesis of MS (Cross et al., 2001) . The most consistent laboratory abnormality found in MS patients is increased intrathecal production of oligoclonal immunoglobulin (Ig), present in N90% of persons with definite MS (Walsh et al., 1985; Trotter and Rust, 1989) . These Igs include IgG, IgA, IgM and IgD (Walsh and Tourtelotte, 1986) . Several studies have correlated high levels of CSF Ig, including both IgG and IgM, with worse prognosis (Olsson and Link, 1973; Villar et al., 2002; Izquierdo et al., 2002) . MS patients lacking CSF oligoclonal bands (OCBs) have a more benign course (Zeman et al., 1996) , whereas higher numbers of OCBs are associated with a poor prognosis (Avasarala et al., 2001) . These studies provide correlative data, but may reflect an altered humoral immune system rather than abnormalities fundamental to pathogenesis.
To better define the role of B cells in MS, we undertook an open-label Phase II clinical trial of B cell depletion in relapsingremitting MS (RRMS) patients with suboptimal response to standard therapies. Serial measurements of serum and cerebrospinal fluid (CSF) Abs to the myelin proteins, myelin oligodendrocyte glycoprotein (MOG) and myelin basic protein (MBP) and serial measures of B and T cells in CSF were performed.
Materials and methods

Study design
This Phase II trial was designed to study the use of rituximab as an add-on therapy in RRMS patients continuing to have MS activity, both clinically and by MRI, despite therapy with an FDA-approved medication. The study was approved 
